Welcome to BioSeeker Group!

Triple Analysis: Apoptosis, Angiogenesis and Antibodies

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5682
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Apoptosis, Angiogenesis and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Angiogenesis and by the compound strategy of Antibodies.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Angiogenesis and Antibodies.

    To find out more about Triple Analysis: Apoptosis, Angiogenesis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Angiogenesis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Angiogenesis and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agennix
AGY Therapeutics
Aida Pharmaceuticals
Aileron Therapeutics
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Alnylam
ALSP
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Amphora
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Avila Therapeutics
Basilea Pharmaceutica
Bayer
Berkeley Lab
BioAlliance Pharma
BioAxone
Biocad
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
Biomas
Bionovo
Biosceptre
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Chlorogen
Choongwae
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
CombinatoRx
Coronado Biosciences
Critical Outcome Technologies
CSL
Cue Biotech
CuraGen
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dompe
Dr Reddy’s
Dyax
Eisai
Elan
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
EpiCept
Ergon Pharmaceuticals
Erimos
EUSA Pharma
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galaxy Biotech
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
GPC Biotech
Green Cross
Harbor BioSciences
Hawthorn Pharmaceuticals
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intracel
Intradigm
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Johnson & Johnson
KAI Pharmaceuticals
Kaketsuken
KaloBios
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Kyto Biopharma
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MAT Biopharma
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Morvus Technology
Mycenax
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
NewSouth Innovations
NIH
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Oasmia
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Onyvax
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanaGin
PanGenetics
Patrys
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacopeia
Pharmacyclics
PharmaMar
Pharminox
Philogen
PhiloGene
Pierre Fabre
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
Protein Sciences
Protgen
PTC Therapeutics
QLT
Ramot
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Rexahn
Rigel
Rosetta Genomics
Sanofi
Santaris Pharma
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Shanghai CP Guojian
Shenogen
Shionogi
Sigma-Tau
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synageva BioPharma
SynDevRx
SynerGene Therapeutics
Tactic Pharma
Taiho
Takeda
Tamir Biotechnology
Targa Therapeutics
Tau Therapeutics
Taxolog
TeGenero
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
UMN Pharma
United Therapeutics
Vaccinex
Wakunaga
ValiRx
VasGene Therapeutics
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
Viragen
Viralytics
ViroTarg
Viventia Biotech
VM Discovery
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
YM BioSciences
Zenotech
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
ABT-510
adecatumumab
AEG-35156
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
alvocidib
amatuximab
AME-133
AMG-386
Angiozyme
apatinib
APG-101
ARQ-197
AS-101
AS-1411
atrasentan
AV-299
axitinib
bardoxolone methyl
belimumab
belinostat
bevacizumab
BHQ880
BIBF-1120
blinatumomab
BMS-663513
BMS-690514
BMS-936558
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
BT-062
BZL-101
canfosfamide hydrochloride
carlumab
catumaxomab
CDX-1307
CDX-1401
cediranib
cenersen
cetuximab
cilengitide
cintredekin besudotox
cixutumumab
CMAB302
CMAB304
conatumumab
crolibulin
CT-011
dalotuzumab
daratumumab
denosumab
DI-17E6
dinaciclib
dovitinib lactate
dulanermin
E-7820
elotuzumab
EMD-273063
EMD525797
endostatin
ENMD-2076
enzastaurin hydrochloride
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
foretinib
fosbretabulin tromethamine
fresolimumab
galiximab
ganitumab
gataparsen
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GliaAtak
GS-6634
GT-111
HBP-347
HE-3235
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
idronoxil
imatinib mesilate
imetelstat
inotuzumab ozogamicin
intetumumab
IPH-2102
ipilimumab
IPP-204106
iratumumab
JI-101
kahalalide F
L19-TNFalpha
lenvatinib
lestaurtinib
linifanib
lintuzumab
LIP-131I
litronesib
lonaprisan
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY-2275796
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MEDI-551
MEDI-573
MGCD-265
midostaurin
milatuzumab
milatuzumab-doxorubicin
MKC-1
MM-111
MM-121
mocetinostat
mogamulizumab
MOR202
MOR208
MORAb-004
motesanib diphosphate
motexafin gadolinium
moxetumomab pasudotox
muparfostat (IV)
naptumomab estafenatox
natalizumab
navitoclax
necitumumab
NGR-TNF
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
ofatumumab
olaratumab
ON-01910
onartuzumab
Oncohist
Onyvax-105
oregovomab
OTS-102
paclitaxel
PancAtak
panitumumab
panobinostat
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
PCI-27483
pegdinetanib
pertuzumab
PF-4856884
plitidepsin
ponatinib
ProstAtak
PTC-299
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
Reditux
regorafenib
retaspimycin
RG-7160
ridaforolimus
rilotumumab
rituximab
robatumumab
romiplostim
sagopilone
samalizumab
SAR-3419
seliciclib
siltuximab
sirolimus
sorafenib tosylate
sotatercept
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
Sym-004
talactoferrin alfa
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
terameprocol
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
tivozanib
TL-32711
tocilizumab
TRC-105
tremelimumab
triciribine phosphate
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
vandetanib
veltuzumab
vismodegib
volasertib
volociximab
vosaroxin
XL-147
XL-184
XL-647
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Angiogenesis and Antibodies.
    To find out more about Triple Analysis: Apoptosis, Angiogenesis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Angiogenesis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Pancreatic Cancer, Prostate Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Lymphoma, Pancreatic Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


The Latest Sales Figures in Oncology Drug Pipeline Update
BioSeeker Group have identified 46 companies plus partners who are today developing 114 The Latest Sales Figures in Oncology drugs in 1477 developmental projects in cancer across 113 different targets. In addition, there are 2 suspended drugs and another 27 drugs where development has been ceased. Learn More


Hematological Cancers - A Therapeutic & Competitive Insight
BioSeeker Group has studied the progress of 125 of the most prominent drugs in development for the treatment of hematological cancers. This extensive 190+ pages report not only describes and analyzes the latest years of progress in lymphoma and leukemia, it also provides an insight and framework to understand this complex field. Learn More